other material
confidence high
sentiment positive
materiality 0.80
Krystal Biotech reports 27% ORR and 73% DCR for inhaled KB707 in advanced NSCLC
Krystal Biotech, Inc.
- ORR of 27% (3 partial responses) and DCR of 73% in 11 evaluable NSCLC patients as of Dec 6, 2024.
- Lung target lesion ORR 36% (3 partial, 1 complete response) and DCR 82%.
- Treatment-emergent AEs mild to moderate; no Grade 4/5 events; outpatient administration feasible.
- Protocol amended to add two combination cohorts (with anti-PD-1 ± chemo) for advanced NSCLC.
- Enrollment ongoing; detailed results to be presented at future scientific meetings.